Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study

M. Hutchings, J. Radford, SM. Ansell, Á. Illés, A. Sureda, JM. Connors, A. Sýkorová, H. Shibayama, JS. Abramson, NS. Chua, JW. Friedberg, J. Kořen, AS. LaCasce, L. Molina, G. Engley, K. Fenton, H. Jolin, R. Liu, A. Gautam, A. Gallamini

. 2021 ; 39 (2) : 185-195. [pub] 20210216

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21018916

Grant support
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Approximately one-third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high-risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON-1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first-line therapy after a median follow-up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD-treated versus ABVD-treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high-risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON-1 shows a favorable benefit-risk balance in high-risk patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018916
003      
CZ-PrNML
005      
20210830100503.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.2838 $2 doi
035    __
$a (PubMed)33462822
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hutchings, Martin $u Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark
245    10
$a Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study / $c M. Hutchings, J. Radford, SM. Ansell, Á. Illés, A. Sureda, JM. Connors, A. Sýkorová, H. Shibayama, JS. Abramson, NS. Chua, JW. Friedberg, J. Kořen, AS. LaCasce, L. Molina, G. Engley, K. Fenton, H. Jolin, R. Liu, A. Gautam, A. Gallamini
520    9_
$a Approximately one-third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high-risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON-1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first-line therapy after a median follow-up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD-treated versus ABVD-treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high-risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON-1 shows a favorable benefit-risk balance in high-risk patients.
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a brentuximab vedotin $x farmakologie $x terapeutické užití $7 D000079963
650    _2
$a dakarbazin $x farmakologie $x terapeutické užití $7 D003606
650    _2
$a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a Hodgkinova nemoc $x farmakoterapie $x patologie $7 D006689
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $x metody $7 D009367
650    _2
$a rizikové faktory $7 D012307
650    _2
$a vinblastin $x farmakologie $x terapeutické užití $7 D014747
655    _2
$a časopisecké články $7 D016428
700    1_
$a Radford, John $u Manchester Academic Health Science Centre, University of Manchester and the Christie NHS Foundation Trust, Manchester, UK
700    1_
$a Ansell, Stephen M $u Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Illés, Árpád $u Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Sureda, Anna $u Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet and Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain
700    1_
$a Connors, Joseph M $u Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada
700    1_
$a Sýkorová, Alice $u University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Shibayama, Hirohiko $u Department of Hematology and Oncology, Osaka University, Osaka, Japan
700    1_
$a Abramson, Jeremy S $u Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
700    1_
$a Chua, Neil S $u Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
700    1_
$a Friedberg, Jonathan W $u Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA
700    1_
$a Kořen, Jan $u First Faculty of Medicine, General University Hospital, Prague, Czech Republic
700    1_
$a LaCasce, Ann Steward $u Dana-Farber Cancer Institute, Boston, Massachusetts, USA
700    1_
$a Molina, Lysiane $u CHU de Grenoble, Grenoble, France
700    1_
$a Engley, Gerald $u Seattle Genetics, Bothell, Washington, USA
700    1_
$a Fenton, Keenan $u Seattle Genetics, Bothell, Washington, USA
700    1_
$a Jolin, Hina $u Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
700    1_
$a Liu, Rachael $u Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
700    1_
$a Gautam, Ashish $u Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
700    1_
$a Gallamini, Andrea $u Research and Innovation Department, Centre Antoine Lacassagne, Nice, France
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 39, č. 2 (2021), s. 185-195
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33462822 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100503 $b ABA008
999    __
$a ok $b bmc $g 1689873 $s 1139362
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 39 $c 2 $d 185-195 $e 20210216 $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
GRA    __
$p Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options